DE69120430D1 - Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen - Google Patents

Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen

Info

Publication number
DE69120430D1
DE69120430D1 DE69120430T DE69120430T DE69120430D1 DE 69120430 D1 DE69120430 D1 DE 69120430D1 DE 69120430 T DE69120430 T DE 69120430T DE 69120430 T DE69120430 T DE 69120430T DE 69120430 D1 DE69120430 D1 DE 69120430D1
Authority
DE
Germany
Prior art keywords
agents
pct
reinforcing
resistance
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69120430T
Other languages
English (en)
Inventor
Ann King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909027367A external-priority patent/GB9027367D0/en
Priority claimed from GB909027402A external-priority patent/GB9027402D0/en
Priority claimed from GB909027358A external-priority patent/GB9027358D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69120430D1 publication Critical patent/DE69120430D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE69120430T 1990-12-18 1991-12-17 Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen Expired - Lifetime DE69120430D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909027367A GB9027367D0 (en) 1990-12-18 1990-12-18 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB909027402A GB9027402D0 (en) 1990-12-18 1990-12-18 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB909027358A GB9027358D0 (en) 1990-12-18 1990-12-18 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
PCT/GB1991/002248 WO1992011034A1 (en) 1990-12-18 1991-12-17 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance

Publications (1)

Publication Number Publication Date
DE69120430D1 true DE69120430D1 (de) 1996-07-25

Family

ID=27265406

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69120430T Expired - Lifetime DE69120430D1 (de) 1990-12-18 1991-12-17 Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen

Country Status (8)

Country Link
US (1) US5416091A (de)
EP (1) EP0563134B1 (de)
JP (1) JPH06504772A (de)
AT (1) ATE139447T1 (de)
AU (1) AU665341B2 (de)
CA (1) CA2098198A1 (de)
DE (1) DE69120430D1 (de)
WO (1) WO1992011034A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661152A (en) * 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
NZ275646A (en) * 1993-10-15 1998-02-26 Schering Corp Tricyclic sulphonamide derivatives and medicaments
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ATE210652T1 (de) * 1993-10-15 2001-12-15 Schering Corp Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
US6075025A (en) 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5464840A (en) * 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5574173A (en) * 1993-12-06 1996-11-12 Schering Corporation Tricyclic derivatives, compositions and methods of use
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5516655A (en) * 1994-04-20 1996-05-14 Eli Lilly And Company Multiple drug resistance gene of Aureobasidium pullulans
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5773214A (en) * 1995-02-27 1998-06-30 Eli Lilly And Company Multiple drug resistance gene of aspergillus flavus
US5705352A (en) * 1995-02-27 1998-01-06 Eli Lilly And Company Multiple drug resistance gene of Aspergillus fumigatus
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5684013A (en) * 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5891872A (en) * 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
IL117797A0 (en) * 1995-04-07 1996-08-04 Pharmacopeia Inc Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
WO1998053811A1 (en) * 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
CZ298511B6 (cs) * 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
PT1073738E (pt) 1998-04-21 2005-01-31 Max Planck Ges Forderung Der W Canal do iao k+ de seres humanos e as suas aplicacoes terapeuticas
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
SK287105B6 (sk) 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
MXPA03003011A (es) 2000-10-05 2003-07-14 George Q Daley Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
CA2681267C (en) * 2007-04-13 2013-11-19 Southern Research Institute Anti-angiogenic agents and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines

Also Published As

Publication number Publication date
EP0563134A1 (de) 1993-10-06
EP0563134B1 (de) 1996-06-19
WO1992011034A1 (en) 1992-07-09
ATE139447T1 (de) 1996-07-15
JPH06504772A (ja) 1994-06-02
CA2098198A1 (en) 1992-06-18
AU9062691A (en) 1992-07-22
AU665341B2 (en) 1996-01-04
US5416091A (en) 1995-05-16

Similar Documents

Publication Publication Date Title
DE69120430D1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
ATE167470T1 (de) Heterocyclische amine zur therapie von asthma und entzündungen der atemwege
EE9800223A (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
DE69027865T2 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
ATE200672T1 (de) Alkoxyalkylcarbamate von imidazo(1,2-a)pyridinen
DE69316013T2 (de) Verwendung von phosphinate zur behandlung der osteoporose
SE9402880D0 (sv) New peptide derivatives
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
ZA937147B (en) Heterocyclic amines useful in the therapy of the asthma and of the inflammation of the respiratory tract
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
DE69207698T2 (de) Arylalkylester der 4,5-dihydoxy-9,10-dihydro-9,10-dioxo-2-anthracencarbonsäure und deren therapeutische verwendung
DE69606777T2 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
DE69124382T3 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
MX9201288A (es) Metodo de tratamiento.
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
SE9401596D0 (sv) New compounds
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
ATE221068T1 (de) Anellierte beta-carboline

Legal Events

Date Code Title Description
8332 No legal effect for de